For its first project, EMERCell is developing a generic cell immunotherapy NK-based to be used in synergy with monoclonal antibodies (MAbs) to treat refractory patients in oncology. This new and innovative drug therapy called NK-001 consists of allogeneic Natural Killer (NK) cells which are produced ex vivo according to a patented process.
NK lymphocytes present natural cytotoxicity and specific cytotoxicity in association with MAbs (Antibody-Dependent Cell Cytotoxicity (ADCC)) and are known for their natural immunology surveillance of cancers.
NK cells being considered as highly potent effectors, two NK-based therapeutic strategies exist:
EMERCell NK-001 solution is an optimized active product, with low incidence of endogenous immune system state, consisting of highly activated & alloreactive allogeneic NK cells. The process allows full industrialization using the same source of NK cells for all patients, and producing high quantities of cells to treat dozens of patients with one batch.
A NK-based mature cell immunotherapy generic product used in synergy with monoclonal antibodies to treat refractory patients in oncology
Immunotherapy to help natural body defenses
Mature cell therapy to supply immune-defective patients with highly active effector cells
Highly activated NK cells-based to have a poorly toxic but highly potent effector
Generic product to be used for many patients & many pathologies
Product acting in synergy with monoclonal antibodies to specifically target different pathologies
check No genetic modification
check Generic therapeutic tool to treat different pathologies
check Weak toxicity and genetic instability risks
check Decreased variability
check Weak incidence of endogenous immune system
check Highly activated NK cells
check Alloreactive allogeneic NK cells
check High MAb receptor expression
check Availability of biological raw material
check High quantity of produced cells